Recruitment

Recruitment Status
Completed
Estimated Enrollment
200

Inclusion Criteria

Participant has completed the 14-day Treatment Period.
Participant is still in need of prolonged release opioid treatment.
Participant does not meet any of the compulsory discontinuation criteria.
Participant has completed the 14-day Treatment Period.
Participant is still in need of prolonged release opioid treatment.
Participant does not meet any of the compulsory discontinuation criteria.

Summary

Conditions
Pain
Type
Interventional
Phase
Phase 2Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: There were 2 arms in Part 1: Randomization was carried out in blocks and in a 2:1 ratio (tapentadol PR to morphine PR). Participants were stratified using interactive response technology: by age group (6 years to less than 12 years and 12 years to less than 18 years, at the second visit [Allocation Visit]) so that at least 25% of participants were in the younger age group, and by underlying pain condition (cancer/non-cancer-related pain). There were 4 arms in Part 2: The investigators/participants decided if participants from Part 1 switched to or continued on tapentadol PR (tapentadol arm) or if they received no treatment/standard of care treatment if needed (2 direct observation arms following treatment in Part 1 and 1 observation arm after initial treatment with tapentadol in Part 2).Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 6 years and 17 years
Gender
Both males and females

Description

During the first 2 weeks of the study (Part 1), participants were given either tapentadol or morphine prolonged-release (PR) tablets. Assignment was done randomly (like tossing a coin). The participant and the caregiver knew which medication the child was taking. The primary endpoint was based on da...

During the first 2 weeks of the study (Part 1), participants were given either tapentadol or morphine prolonged-release (PR) tablets. Assignment was done randomly (like tossing a coin). The participant and the caregiver knew which medication the child was taking. The primary endpoint was based on data collected in Part 1 of this study. If eligible and willing, participants from Part 1 could enter a 12 month follow-up period (Part 2). In Part 2 of this study, participants were either treated with tapentadol PR tablets or entered observations arms where they were not treated at all or with standard of care.

Inclusion Criteria

Participant has completed the 14-day Treatment Period.
Participant is still in need of prolonged release opioid treatment.
Participant does not meet any of the compulsory discontinuation criteria.
Participant has completed the 14-day Treatment Period.
Participant is still in need of prolonged release opioid treatment.
Participant does not meet any of the compulsory discontinuation criteria.

Tracking Information

NCT #
NCT02151682
Collaborators
Not Provided
Investigators
Study Director: Director Clinical Trials Grünenthal GmbH